Refine Search
(182)
(276)
(843)
(1751)

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) – Opportunity Analysis and Forecasts to 2025

  • $10,995
  • February 2017
Add to Basket Quick View Add to Saved List

Immune Thrombocytopenia (ITP) is an auto-immune-related bleeding disorder characterized by a low platelet count. Patients with severe ITP often experience fatigue, bruising, and reduced quality of life. Although most ITP cases are not fatal, ap...

PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • February 2017
Add to Basket Quick View Add to Saved List

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Austr...

OpportunityAnalyzer: Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025

  • $10,995
  • April 2017
Add to Basket Quick View Add to Saved List

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneit...

PharmaPoint: Ulcerative Colitis– Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • January 2017
Add to Basket Quick View Add to Saved List

Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon's ability to absorb water is decreased, which leads to progressive loosening of the...

PharmaPoint: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • March 2013
Add to Basket Quick View Add to Saved List

Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current dis...

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • February 2013
Add to Basket Quick View Add to Saved List

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • December 2016
Add to Basket Quick View Add to Saved List

The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Fla...

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • December 2012
Add to Basket Quick View Add to Saved List

GlobalData's report "Prostate Cancer - Global Drug Forecast and Market Analysis to 2022" provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifies and analyses the key...

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • May 2013
Add to Basket Quick View Add to Saved List

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. T...

PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • May 2016
Add to Basket Quick View Add to Saved List

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of i...

PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending ...

PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious glob...

PharmaPoint: Peripheral Artery Disease — Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • October 2015
Add to Basket Quick View Add to Saved List

In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth ...

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • April 2016
Add to Basket Quick View Add to Saved List

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Altho...

PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for ...

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

DES, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocul...

PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major tr...

PharmaPoint: Bipolar Disorder – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • March 2016
Add to Basket Quick View Add to Saved List

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most chal...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • September 2016
Add to Basket Quick View Add to Saved List

Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination that have a significant social impact through disruptions at school, work, home,...

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $10,995
  • October 2016
Add to Basket Quick View Add to Saved List

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of en...

PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • May 2016
Add to Basket Quick View Add to Saved List

GlobalData estimates sales of HF therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of $11.5B by 2025. T...

PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • June 2016
Add to Basket Quick View Add to Saved List

The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this per...

PharmaPoint: Acute Coronary Syndrome – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • August 2016
Add to Basket Quick View Add to Saved List

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary art...

PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • August 2016
Add to Basket Quick View Add to Saved List

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality a...

PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • August 2016
Add to Basket Quick View Add to Saved List

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will r...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • November 2016
Add to Basket Quick View Add to Saved List

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stage...

PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • November 2016
Add to Basket Quick View Add to Saved List

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorgani...

PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • May 2014
Add to Basket Quick View Add to Saved List

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is ...

PharmaPoint: Non-Small Cell Lung Cancer – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • April 2014
Add to Basket Quick View Add to Saved List

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • September 2014
Add to Basket Quick View Add to Saved List

During the forecast period from 2012–2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC p...

OpportunityAnalyzer: Opioid-Induced Constipation – Opportunity Analysis and Forecasts to 2019

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

The Opioid-Induced Constipation (OIC) is a new and rapidly establishing market currently dominated by OTC laxatives set to undergo substantial growth between 2014 and 2019. The main drivers of growth will be an increase in the diagnosed OIC pop...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • February 2015
Add to Basket Quick View Add to Saved List

The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta’s launch, patients’ uptake has remained low, but due to ...

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • May 2015
Add to Basket Quick View Add to Saved List

Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the f...

PharmaPoint: Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • June 2015
Add to Basket Quick View Add to Saved List

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any a...

OpportunityAnalyzer: Axial Spondyloarthritis – Opportunity Analysis and Forecast to 2024

  • $10,995
  • July 2015
Add to Basket Quick View Add to Saved List

Ankylosing Spondylitis (AS) is an autoimmune disease that causes inflammation of the sacroiliac joint accompanied by pain and stiffness of the lower back, which typically gets better with exercise. Ankylosis (fusion) of the spine is typically a...

PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

Meningococcal disease is an acute infection caused by the bacterium Neisseria meningitidis, an aerobic, gram-negative diplococcal microbe that is only pathogenic in humans. Different N. meningitides strains are typically classified into serotyp...

OpportunityAnalyzer: Graft-Versus-Host Disease – Opportunity Analysis and Forecasts to 2023

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in t...

OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2017

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

The bladder cancer market has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition,...

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • July 2013
Add to Basket Quick View Add to Saved List

There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lack...

OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and sple...

OpportunityAnalyzer: Myasthenia Gravis – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • June 2015
Add to Basket Quick View Add to Saved List

Myasthenia gravis is an autoimmune disease affecting the nervous system . While myasthenia gravis is a rare disease, it is considered to be the most common neuromuscular disorder and presents itself as a weakness of the muscles. In the majority...

OpportunityAnalyzer: Genital Herpes – Opportunity Analysis and Forecasts to 2023

  • $10,995
  • July 2015
Add to Basket Quick View Add to Saved List

Genital herpes (GH) is a life-long viral infection of the genitalia and urogenital tract. It is one of the most common sexually transmitted infections (STIs) and is a leading cause of genital ulcers around the world. Patients with GH can suffer...

OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecast to 2024

  • $10,995
  • August 2015
Add to Basket Quick View Add to Saved List

GlobalData estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sale...

OpportunityAnalyzer: Clostridium difficile Infections (CDIs) – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • October 2015
Add to Basket Quick View Add to Saved List

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated ...

OpportunityAnalyzer: Fabry Disease - Opportunity Analysis and Forecast to 2024

  • $10,995
  • August 2015
Add to Basket Quick View Add to Saved List

GlobalData estimates the 2014 sales for the Fabry disease market at approximately $682m across the 7MM. The US contributed the majority of these sales, generating an estimated $295m. By the end of the forecast period in 2024, Fabry disease sale...

OpportunityAnalyzer: Benign Prostatic Hyperplasia – Opportunity Analysis and Forecast to 2024

  • $10,995
  • September 2015
Add to Basket Quick View Add to Saved List

GlobalData estimates the 2014 sales for the benign prostatic hyperplasia (BPH) therapeutics market at approximately $2 billion across the 7MM (US, Germany, France, Italy, Spain, UK and Japan). The US contributed a significant majority of these ...

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chim...

OpportunityAnalyzer: Osteoarthritis – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • June 2016
Add to Basket Quick View Add to Saved List

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes t...

OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) – Opportunity Analysis and Forecast to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Systemic sclerosis (SSc) is a complex autoimmune disease that affects the skin and multiple internal organs. Common manifestations of SSc that are included in this report are skin fibrosis, lung fibrosis, and digital vasculopathy (including Ray...

OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report...

OpportunityAnalyzer: Hepatocellular Carcinoma – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver cancer, accounting for approximately 85...

OpportunityAnalyzer: Gaucher Disease – Opportunity Analysis and Forecast to 2024

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

GlobalData estimated the 2014 sales for the Gaucher Disease (GD) market at approximately $875m across the 7MM (US, France, Germany, Italy, Spain, UK, and Israel). The US market contributed the majority of these sales, generating an estimated $4...

OpportunityAnalyzer: Sjogren’s Syndrome - Opportunity Analysis and Forecast to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Sjögren’s syndrome (SS) is a slow progressing chronic autoimmune disease, which predominantly affects middle-aged women, and is characterized by lymphocytic infiltration of the exocrine glands, mainly the lacrimal and salivary glands, resulting...

OpportunityAnalyzer: Pulmonary Arterial Hypertension – Opportunity Analysis and Forecast to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

GlobalData estimates the 2014 sales for pulmonary arterial hypertension (PAH) at approximately $3.45 billion across the 7MM covered in this report, which include the US, 5EU and Japan. The market will grow moderately at a CAGR of 3.20% during t...

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high leve...

OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but ov...

OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecast to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inabil...

OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma – Opportunity Analysis and Forecast to 2024

  • $10,995
  • February 2016
Add to Basket Quick View Add to Saved List

The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of gro...

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024

  • $10,995
  • January 2016
Add to Basket Quick View Add to Saved List

Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one ...

OpportunityAnalyzer: Huntington’s Disease – Opportunity Analysis and Forecast to 2024

  • $10,995
  • May 2016
Add to Basket Quick View Add to Saved List

HD is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Approved treatments for HD across the 7MM are extremely limited, consisting of...

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025

  • $10,995
  • June 2016
Add to Basket Quick View Add to Saved List

The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it w...

OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecast to 2025

  • $10,995
  • November 2016
Add to Basket Quick View Add to Saved List

Endometriosis is an estrogen-dependent, chronic, inflammatory disease characterized by the appearance and growth of endometrial cells or tissues in locations outside the uterus. It is a common gynecological condition; however the disease is und...

OpportunityAnalyzer: Myelofibrosis – Opportunity Analysis and Forecasts to 2025

  • $10,995
  • November 2016
Add to Basket Quick View Add to Saved List

Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is only one approved drug, Incyte/Novartis' Jakafi (ruxolitinib), for the treatment of MF, and other conventional therapies used i...

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

  • $10,995
  • April 2013
Add to Basket Quick View Add to Saved List

Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most seve...

PharmaPoint: Melanoma – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • April 2015
Add to Basket Quick View Add to Saved List

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1...

PharmaPoint: Type 1 Diabetes – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • March 2015
Add to Basket Quick View Add to Saved List

Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at ...

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • March 2014
Add to Basket Quick View Add to Saved List

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to mai...

PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • February 2015
Add to Basket Quick View Add to Saved List

Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent ...

PharmaPoint: Methicillin-Resistant Staphylococcus aureus (MRSA) — Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • December 2015
Add to Basket Quick View Add to Saved List

With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without any major complications. However, clinicians s...

PharmaPoint: Fibromyalgia – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • May 2015
Add to Basket Quick View Add to Saved List

The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is app...

PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • May 2015
Add to Basket Quick View Add to Saved List

GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4...

PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • October 2014
Add to Basket Quick View Add to Saved List

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or b...

Pharmapoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • May 2015
Add to Basket Quick View Add to Saved List

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage,...

PharmaPoint: Allergic Rhinitis – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • September 2015
Add to Basket Quick View Add to Saved List

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will s...

PharmaPoint: Multiple Myeloma – Global Drug Forecast and Market Analysis to 2023

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti ...

Join our mailing list
Find out first about the latest reports and offers.
Report Catalogue

Strategic Insight Reports

Market Analysis Reports

Databooks